United Therapeutics Revenue decreased by 1.1% to $781.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.6%, from $794.40M to $781.50M. Over 4 years (FY 2021 to FY 2025), Revenue shows an upward trend with a 17.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growth in market share or higher demand, while a decrease may signal market saturation or competitive pressure.
Represents the total consideration received from customers for the sale of goods or services, excluding any sales-relate...
Standard across all public companies; comparable to 'Net Sales' or 'Total Revenue' at peer distributors.
other_revenue_from_contract_with_customer_excluding_asse_0d5b70| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $446.50M | $444.70M | $415.20M | $461.90M | $466.90M | $516.00M | $491.50M | $506.90M | $596.50M | $609.40M | $614.70M | $677.70M | $714.90M | $748.90M | $735.90M | $794.40M | $798.60M | $799.50M | $790.20M | $781.50M |
| QoQ Change | — | -0.4% | -6.6% | +11.2% | +1.1% | +10.5% | -4.7% | +3.1% | +17.7% | +2.2% | +0.9% | +10.2% | +5.5% | +4.8% | -1.7% | +7.9% | +0.5% | +0.1% | -1.2% | -1.1% |
| YoY Change | — | — | — | — | +4.6% | +16.0% | +18.4% | +9.7% | +27.8% | +18.1% | +25.1% | +33.7% | +19.8% | +22.9% | +19.7% | +17.2% | +11.7% | +6.8% | +7.4% | -1.6% |